Track Mind Medicine (MindMed) Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Mind Medicine (MindMed) Inc. MMED.NE · Stock Open Mind Medicine (MindMed) Inc. in new tab

14.90 CAD
Add to portfolio
EPS
-3.31
P/B
6.31
ROE
-85.59
Beta
2.62
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 6, 2026
EPS-3.31
Book Value2.36
Price to Book6.31
Debt/Equity31.38
% Insiders0.594%
Estimates
Forward P/E-6.03
Forward EPS-2.47

DCF Valuation

Tweak assumptions to recompute fair value for Mind Medicine (MindMed) Inc. (MMED.NE)
Currency: CAD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Mind Medicine (MindMed) Inc. Logo Mind Medicine (MindMed) Inc. Analysis (MMED.NE)

United States Health Care Official Website Stock

Is Mind Medicine (MindMed) Inc. a good investment? Mind Medicine (MindMed) Inc. (MMED.NE) is currently trading at 14.90 CAD.

Earnings Schedule: Mind Medicine (MindMed) Inc. is expected to release its next earnings report on May 6, 2026. The market consensus estimate for Forward EPS is -2.47.

Investor FAQ

Does Mind Medicine (MindMed) Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Mind Medicine (MindMed) Inc.?

Mind Medicine (MindMed) Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 6, 2026. The company currently has a trailing EPS of -3.31.

Company Profile

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Exchange Ticker
PNK (United States) MMDWF
NCM (Australia) MNMD
PNK (United States) MMEDF
NEO (Canada) MMED.NE
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Community Discussion